Completely agree with what you have outlined below. Why no BLA 5 years post data lock when it’s the most lucrative market in the world, and over 50% of the world’s immunotherapy revenue comes from US. Why explore compassionate use in the US moving forward when you could have applied BLA or still can anytime?
It tells you that they know that FDA is going to reject their application with the data and regulatory framework they have currently. They have hidden this from shareholders for years and still continue to not disclose this.
All time lows coming soon. Also, I expect quite a few longs go short on the stock if and when there is ever a UK approval in 2026, and a modest spike along with it. It will be easy money because folks know the state of affairs at NWBO very well by now. No hiring, no reimbursement in UK, no plans for US submission in the coming years, big capital requirement to pay off existing loans, continue with ongoing operations, run new clinical trial(s), invest in development of Eden, manufacturing, UK commercialization, and the list goes on. Only shorts and LP’s financiers are able to consistently make money on this stock. The bag holders simply enjoy averaging down and living in denial with all the excuses! But these bag holders are necessary so LP’s financiers, and shorts can consistently make money and the management can take home their hefty salaries every month! ;)
Market Data 
Markets 
